Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by woundedkneeon Oct 15, 2021 2:49pm
367 Views
Post# 34011170

The share price

The share priceThe share price was staying in the 1.20 range on the hope of a positive revision of the otenaproxesul situation. This drug ,as of yesterday, is now dead in the water. Even the spin putting it to be a pain reliever for post op is miles away from acceptance. Nasdag listing is dead. Dan has been on the edge of betraying his shareholders from the phase two trials and the low dose exclusion, plus the questionable sale (twice) of thousands of shares, quite conveniently I might add. He must go, regardless of what Mugsy says. His credibility is shot imo. This from a past shareholder who lost 120 grand based on his glowing update just a mere 7 days before the crash.  There has to be new blood to head up this company if only to rebuild credibility. Too many questions remained unanswered.  Of course this is only my opinion.
<< Previous
Bullboard Posts
Next >>